Who is sponsoring NCT01032850?

NCT01032850 is sponsored by New Mexico Cancer Research Alliance.

What condition does NCT01032850 study?

NCT01032850 studies Hepatocellular Carcinoma.

What drugs are being tested in NCT01032850?

Interventions: Sorafenib & Capecitabine.

What is the status of NCT01032850?

NCT01032850 is currently TERMINATED.

Last reviewed 2021-05-11 · How we verify

Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

NCT01032850 Phase 2 TERMINATED Results posted

This research study will evaluate Sorafenib (Nexavar®) and Capecitabine (Xeloda®) to see the following: * how effective this combination of study drugs will be in treating HCC * how long subjects respond to these study drugs * what types of side effects can be expected, and * how severe the side effects are All subjects in this study will receive: * Sorafenib twice a day by mouth * Capecitabine twice a day by mouth Treatment will be given in a 28-day treatment cycle. Subjects will take sorafenib every day of the cycle. Subjects will take capecitabine on days 1-7 and 15-21 of the cycle

Details

Lead sponsor	New Mexico Cancer Research Alliance
Phase	Phase 2
Status	TERMINATED
Enrolment	15
Start date	2009-09
Completion	2017-08

Conditions

Hepatocellular Carcinoma

Interventions

Sorafenib & Capecitabine

Primary outcomes

Number of Participants Experiencing Adverse Events — 6 months
The primary objective of the study is to evaluate safety and tolerability of the study treatment regimen. The analyses will be descriptive and no formal hypotheses testing will be performed. Toxicities (i.e. Adverse Events) are evaluated prior to each treatment and during any clinical visit.

Countries

United States